World Library  
Flag as Inappropriate
Email this Article

Progressive multifocal leukoencephalopathy


Progressive multifocal leukoencephalopathy

Progressive multifocal leukoencephalopathy
Classification and external resources
ICD-10 A81.2
ICD-9 046.3
DiseasesDB 10718
MedlinePlus 000674
eMedicine radio/573
MeSH D007968

Progressive multifocal leukoencephalopathy (PML) is a rare and usually fatal viral disease characterized by progressive damage (-pathy) or inflammation of the white matter (leuko-) of the brain (-encephalo-) at multiple locations (multifocal). It is caused by the JC virus, which is normally present and kept under control by the immune system. JC virus is harmless except in cases of weakened immune systems. In general, PML has a mortality rate of 30-50 percent in the first few months and those who survive can be left with varying degrees of neurological disabilities.

PML occurs almost exclusively in patients with severe immune deficiency, most commonly among patients with acquired immune deficiency syndrome (AIDS), but people on chronic immunosuppressive medications including chemotherapy are also at increased of PML, such as patients with transplants, Hodgkin's Lymphoma, multiple sclerosis, psoriasis and other autoimmune diseases.


  • Cause 1
    • JC Virus infection 1.1
    • Immunosuppression 1.2
  • Pathogenesis 2
  • Symptoms 3
  • Diagnosis 4
  • Treatment 5
  • Prognosis 6
  • In multiple sclerosis 7
  • See also 8
  • References 9
  • External links 10


JC Virus infection

The cause of PML is a type of polyomavirus called the JC virus (JCV), after the initials of the patient from whose tissue the virus was first successfully cultured. Recent publications indicate 39%[1] to 58%[2] of the general population are seropositive for antibodies to JCV, indicating current or previous infection with the virus. JCV causes persistent asymptomatic infection in approximately one-third of the adult population, based on viral shedding into the urine from the site of asymptomatic infection in the kidney. The virus causes disease only when the immune system has been severely weakened.


PML is most common in people with HIV1 infection; prior to the advent of effective antiretroviral therapy, as many as 5% of people with AIDS eventually developed PML.[3] It is unclear why PML occurs more frequently in AIDS than in other immunosuppressive conditions; some research suggests the effects of HIV on brain tissue, or on JCV itself, make JCV more likely to become active in the brain and increase its damaging inflammatory effects.[4]

PML can occur in people on chronic immunosuppressive therapy like corticosteroids, for organ transplant,[5] in people with cancer (such as Hodgkin’s disease[6] or lymphoma) and individuals with autoimmune diseases such as multiple sclerosis,[7] rheumatoid arthritis, psoriasis,[8] and systemic lupus erythematosis with or without biological therapies that depress the immune response and allow JC virus reactivation.[3] These therapies include efalizumab,[8] belatacept,[9] rituximab,[10] natalizumab,[7] infliximab,[11] cytotoxic chemotherapy,[12] corticosteroids,[13] and various transplant drugs such as tacrolimus.[14]


PML is a demyelinating disease, in which the myelin sheath covering the axons of nerve cells is gradually destroyed, impairing the transmission of nerve impulses. It affects the subcortical white matter, particularly that of the parietal and occipital lobes. PML destroys oligodendrocytes and produces intranuclear inclusions. PML is similar to another demyelinating disease, multiple sclerosis, but progresses much more quickly. The breakdown of myelin is commensurate with the degree of immunocompromise.


Symptoms can develop over several weeks to months. Symptoms depend on location of damage in the brain and the degree of damage. The most prominent symptoms are "clumsiness, progressive weakness and visual, speech, and sometimes personality changes"[3] The lesions affecting the parietal and occipital lobes can lead to a phenomenon known as alien hand syndrome.


T2-weighted MRI showing progressive multifocal leukoencephalopathy

PML is diagnosed in a patient with a progressive course of the disease, finding JC virus DNA in spinal fluid together with consistent white matter lesions on brain magnetic resonance imaging (MRI); alternatively, a brain biopsy is diagnostic[3] when the typical histopathology of demyelination, bizarre astrocytes, and enlarged oligodendroglial nuclei are present, coupled with techniques showing the presence of JC virus.[15]

Characteristic evidence of PML on brain CT scan images are multifocal, non-contrast enhancing hypodense lesions without mass effect, but MRI is far more sensitive than CT.[15] The most common area of involvement is the cortical white matter of frontal and parieto- occipital lobes, but lesions may occur anywhere in the brain, like the basal ganglia, external capsule, and posterior cranial fossa structures like the brainstem and cerebellum.[15] Although typically multifocal, natalizumab-associated PML is often monofocal, predominantly in the frontal lobe.[15]


There are no effective drugs that inhibit or cure the virus infection without toxicity. Therefore treatment aims at reversing the immune deficiency to slow or stop the disease progress. In patients on immunosuppression this means stopping the drugs or using plasma exchange to accelerate the removal of the biologic agent that put the person at risk for PML.[3]

In HIV infected people this may mean starting highly active antiretroviral therapy (HAART). AIDS patients starting HAART after being diagnosed with PML tend to have a slightly longer survival time than patients who were already on HAART and then develop PML.[16] Some AIDS patients with PML have been able to survive for several years, with HAART. A rare complication of effective HAART is immune reconstitution inflammatory syndrome (IRIS), in which increased immune system activity actually increases the damage caused by the JCV infection; Although IRIS can often be managed with medication, it is extremely dangerous in PML.[17]

Cidofovir was studied as possible treatment for PML[18] and has been used on a case by case basis, working in some but not not others.

Cytarabine (also known as ARA-C), a chemotherapy drug used to treat certain cancers, has been prescribed on an experimental basis for a small number of non-AIDS PML patients and stabilized the neurological condition of a minority of these patients.[19] One patient regained some cognitive function lost as a result of PML.[20]

In June 2010, the first case report appeared of a PML patient being successfully treated with the anti malaria drug mefloquine with activity against the JC virus. The patient cleared the virus and had no further neurological deterioration.[21]

Two case reports of using interleukin-2 successfully have been published.[22]

A number of drugs work against JC Virus in cell culture, but there is no proven, effective therapy in humans.[23] For example, 1-O-hexadecyloxypropyl-cidofovir (CMX001), suppresses JCV[24] but has been found to have toxicity at therapeutic dosage. The number of patients treated with other therapies is too low to demonstrate effectiveness.


One third up to one half of people with PML die in the first few months following diagnosis, depending on the severity of their underlying disease. Survivors can be left with variable degrees of neurological disabilities.[3]

In multiple sclerosis

Natalizumab was approved in 2004 by the FDA for multiple sclerosis (MS). It was subsequently withdrawn from the market by its manufacturer after it was linked with three cases of PML.[7] All 3 initial cases were taking natalizumab in combination with interferon beta-1a.[7] After a safety review the drug was returned to the market in 2006 as a monotherapy for MS under a special prescription program.[7] As of May 2011, over 130 cases of PML had been reported in MS patients, all in patients who had taken natalizumab for more than a year.[7] While none of them had taken the drug in combination with other disease-modifying treatments, previous use of MS treatments increases the risk of PML between 3 and 4-fold.[7] The estimated prevalence of PML in MS is 1.5 cases per thousand natalizumab users.[7] Around 20% of MS patients with PML die, and most of the rest are very disabled.[7]

See also


  1. ^ Kean, Jaime M.; Rao, Suchitra; Wang, Michael; Garcea, Robert L. (2009). Atwood, Walter J, ed. "Seroepidemiology of Human Polyomaviruses". PLoS Pathogens 5 (3): e1000363.  
  2. ^ Egli, Adrian; Infanti, Laura; Dumoulin, Alexis; Buser, Andreas; Samaridis, Jacqueline; Stebler, Christine; Gosert, Rainer; Hirsch, Hans H. (2009). "Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors". The Journal of Infectious Diseases 199 (6): 837–46.  
  3. ^ a b c d e f "Progressive Multifocal Leukoencephalopathy Information Page". National Institute of Neurological Disorders and Stroke. National Institutes of Health. 14 February 2014. Retrieved 26 November 2014. 
  4. ^ Berger, Joseph (2003). "Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions".  
  5. ^ Mateen, FJ; Muralidharan, R; Carone, M; Van De Beek, D; Harrison, DM; Aksamit, AJ; Gould, MS; Clifford, DB; Nath, A (2011). "Progressive multifocal leukoencephalopathy in transplant recipients". Annals of neurology 70 (2): 305–22.  
  6. ^ "FDA Approval for Brentuximab Vedotin". 
  7. ^ a b c d e f g h i Kappos, Ludwig; Bates, David; Edan, Gilles; Eraksoy, Mefkûre; Garcia-Merino, Antonio; Grigoriadis, Nikolaos; Hartung, Hans-Peter; Havrdová, Eva; Hillert, Jan; Hohlfeld, Reinhard; Kremenchutzky, Marcelo; Lyon-Caen, Olivier; Miller, Ariel; Pozzilli, Carlo; Ravnborg, Mads; Saida, Takahiko; Sindic, Christian; Vass, Karl; Clifford, David B; Hauser, Stephen; Major, Eugene O; O'Connor, Paul W; Weiner, Howard L; Clanet, Michel; Gold, Ralf; Hirsch, Hans H; Radü, Ernst-Wilhelm; Sørensen, Per Soelberg; King, John (August 2011). "Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring". Lancet neurology 10 (8): 745–58.  
  8. ^ a b Peggy Peck (11 February 2009). "SDEF: Third Psoriatic PML Case Raises More Concerns About Efalizumab". MedPage. MedPage Today, LLC. 
  9. ^ "Drug to Help Transplants Wins Support". The Wall Street Journal. 2 March 2010. 
  10. ^ "Off-Label Use of Rituxan Linked to Fatal Leukoencephalopathy". MedScape. WebMD LLC. 
  11. ^ Kumar, Deepak; Bouldin, Thomas W.; Berger, Robert G. (2010). "A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab". Arthritis Rheum 62 (11): 3191–5.  
  12. ^ Connolly, Roisin M.; Doherty, Colin P.; Beddy, Peter; O'Byrne, Ken (2007). "Chemotherapy induced reversible posterior leukoencephalopathy syndrome". Lung Cancer 56 (3): 459–63.  
  13. ^ Viallard, J. F.; Lazaro, E.; Ellie, E.; Eimer, S.; Camou, F.; Caubet, O.; Lafon, M. E.; Fleury, H.; Pellegrin, J. L. (2007). "Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis". Infection 35 (1): 33–6.  
  14. ^ Junna, M. R; Rabinstein, A. A (2007). "Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma". J. Neurol. Neurosurg. Psychiatr. 78 (12): 1410–1.  
  15. ^ a b c d Berger JR; Aksamit AJ; Clifford DB; et al (9 April 2013). "PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section". Neurology 80 (15): 1430–8.  
  16. ^ Wyen, Christoph; Hoffmann, Christian; Schmeier, Norbert; Hoffmann, Andrej; Qurishi, Nazifa; Rockstroh, Jürgen; Esser, Stefan; Rieke, Ansgar; Ross, Birgit; Lorenzen, Thore; Schmitz, Karina; Stenzel, Werner; Salzberger, Bernd; Fätkenheuer, Gerd (2004). "Progressive multifocal leukencephalopathy in patients on highly active antiretroviral therapy: survival and risk factors of death". Journal of Acquired Immune Deficiency Syndrome 37 (2): 1263–1268.  
  17. ^ Vendrely, Aurélie; Bienvenu, Boris; Gasnault, Jacques; Thiebault, Jean Baptiste; Salmon, Dominique; Gray, Françoise (April 2005). "Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy". Acta Neuropathol. 109 (4): 449–55.  
  18. ^ Segarra-Newnham, Marisel; Vodolo, Kristen M (June 2001). "Use of cidofovir in progressive multifocal leukoencephalopathy". Ann Pharmacother 35 (6): 741–4.  
  19. ^ Aksamit, A J (August 2001). "Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside". J. Neurovirol. 7 (4): 386–90.  
  20. ^ Langer-Gould, Annette; Atlas, Scott W.; Green, Ari J.; Bollen, Andrew W.; Pelletier, Daniel (July 2005). "Progressive multifocal leukoencephalopathy in a patient treated with natalizumab". N. Engl. J. Med. 353 (4): 375–81.  
  21. ^ Gofton, T. E.; Al-Khotani, A.; O'Farrell, B.; Ang, L. C.; McLachlan, R. S. (June 2010). "Mefloquine in the treatment of progressive multifocal leukoencephalopathy". J Neurol Neurosurg Psychiatry 82 (4): 452–455.  
  22. ^ Buckanovich RJ1, Liu G, Stricker C, et al (July 2002). "Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy.". Ann Hematol. 81 (7): 410–3.  
  23. ^ Ferenczy, MW; Marshall, LJ; Nelson, CD; Atwood, WJ; Nath, A; Khalili, K; Major, EO (July 2012). "Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.". Clin. Microbiol. Rev. 25 (3): 471–506.  
  24. ^ Gosert, R; Rinaldo, C.H.; Wernil, M; Major, EO; Hirsch, HH (May 2011). "CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes.". Antimicrob. Agents. Chemother. 55 (5): 2129–36.  

External links

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.